**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 1058

**Columns: ORIGINAL ARTICLES**

**Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver**

Chowdhury S *et al*. *DPP8* and *DPP9* in lymphocytes and liver injury

Sumaiya Chowdhury, Yiqian Chen, Tsun-Wen Yao, Katerina Ajami, Xin M Wang, Yury Popov, Detlef Schuppan, Patrick Bertolino, Geoffrey W McCaughan, Denise MT Yu, Mark D Gorrell

**Sumaiya Chowdhury, Yiqian Chen, Tsun-Wen Yao, Katerina Ajami, Xin M Wang, Patrick Bertolino, Geoffrey W McCaughan, Denise MT Yu, Mark D Gorrell,** Molecular Hepatology, Centenary Institute, Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia

**Yury Popov, Detlef Schuppan,** Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States

**Author contributions:** Chowdhury S and Chen Y performed majority of experiments, analyzed and interpreted data; Chowdhury S wrote manuscript; Yao TW and Ajami K performed experiments; Wang XM, Schuppan D, Popov Y and Bertolino P provided consultation; Schuppan D and Popov Y performed part of the experiments; Most studies took place in McCaughan GW’s laboratory; Yu DMT and Gorrell MD designed and supervised and critically revised and reviewed manuscript.

**Supported by** Australian National Health and Medical Research Council Grant 512282 to Gorrell MD; Rebecca L Cooper Foundation Equipment Grants to Gorrell MD; University of Sydney International Scholarship to Chen Y; Australian Postgraduate Scholarship to Yao TW; and Grant NIH U19 AI066313 to Schuppan D

**Correspondence to: Mark D Gorrell, MD, PhD, Associate Professor,** Molecular Hepatology, Centenary Institute, Sydney Medical School, Locked Bag No. 6, Newtown, Sydney, NSW 2042,

Australia. m.gorrell@centenary.usyd.edu.au

**Telephone:** +61-2-95656156 **Fax:** +61-2-95656101

**Received:** November 7, 2012  **Revised:** January 17, 2013

**Accepted :** February 2, 2013

**Published online :**

**Abstract**

**Aim:** To investigate the expression of dipeptidyl peptidase (*DPP*) *8* and *DPP9* in lymphocytes and various models of liver fibrosis.

**Methods:** *DPP8* and *DPP9* expression were measured in mouse splenic CD4+ T-cells, CD8+ T-cells and B-cells (B220+), human lymphoma cell lines and mouse splenocytes stimulated with pokeweed mitogen (PWM) or lipopolysaccharide (LPS), and in dithiothreitol (DTT) and mitomycin-C treated Raji cells. *DPP8* and *DPP9* expression were measured in epidermal growth factor (EGF) treated Huh7 hepatoma cells, in fibrotic liver samples from mice treated with carbon tetrachloride (CCl4) and from *Mdr2* gene knock out (GKO) mice with biliary fibrosis, and in human end stage primary biliary cirrhosis.

**Results:** All three lymphocyte subsets expressed *DPP8* and *DPP9* mRNA. *DPP8* and *DPP9* expression were upregulated in both PWM and LPS stimulated mouse splenocytes and in both Jurkat T- and Raji B-cell lines. *DPP8* and *DPP9* were downregulated in DTT treated and upregulated in mitomycin-C treated Raji cells. *DPP9*-transfected Raji cells exhibited more Annexin V+ cells and associated apoptosis. *DPP8* and *DPP9* mRNA were upregulated in CCl4 induced fibrotic livers but not in the lymphocytes isolated from such livers, while *DPP9* was upregulated in EGF stimulated Huh7 cells. In contrast, intrahepatic *DPP8* and *DPP9* mRNA expression levels were low in the *Mdr2* GKO mouse and in human primary biliary cirrhosis compared to non-diseased livers.

**Conclusion:** These expression patterns point to biological roles for *DPP8* and *DPP9* in lymphocyte activation and apoptosis and in hepatocytes during liver disease pathogenesis.

©2013 Baishideng. All rights reserved.

**Key words:** Dipeptidyl peptidase; CD26; Lymphocytes; Liver fibrosis; Biliary fibrosis

Chowdhury S, Chen Y, Yao TW, Ajami K, Wang XM, Popov Y, Schuppan D, Bertolino P, McCaughan GW, Yu DMT, Gorrell MD. Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.

*World J Gastroenterol* 2013;

**Available from:** URL: http://www.wjgnet.com/esps/

**DOI:** http://dx.doi.org/10.3748/wjg.v19.i0.0000

**Introduction**

The four enzyme members of the dipeptidyl peptidase (*DPP*) *4* gene family, *DPP4*, fibroblast activation protein (FAP), *DPP8* and *DPP9*, have attracted considerable research interest in recent years since *DPP4* inhibitors became a successful therapy for type 2 diabetes[[1](#_ENREF_1),[2](#_ENREF_2)].FAP is a potential cancer therapeutic target[[2](#_ENREF_2),[3](#_ENREF_3)]. *DPP4*, the most well characterized family member, has ubiquitous cell surface and extracellular expression[[2](#_ENREF_2),[4-7](#_ENREF_4)]. *DPP8* and *DPP9* are the most recently discovered members of the *DPP4* gene family[[8-11](#_ENREF_8)]. *DPP4*, *DPP8* and *DPP9* are ubiquitously expressed cytosolic enzymes with *DPP4*-like activity[[8](#_ENREF_8), [11](#_ENREF_11),[12](#_ENREF_12)]. They are expressed by major epithelial organs including liver, colon, small intestine, stomach, lung, skin, tongue, kidney, testis and the lymphoid cells of lymph node, blood, thymus, and spleen[[13](#_ENREF_13)]. The biological functions of *DPP8* and *DPP9* are largely uncharacterized.

*DPP4* is also known as CD26 and has important roles in the immune system. It is a costimulatory molecule in T cell activation and proliferation and is critical in the development of T helper (Th) 1 responses to foreign antigens. It is expressed at detectable levels by some resting T cells but the cell surface expression increases 5-10 fold following stimulation with antigen or anti-CD3+ interleukin-2 or with mitogens such as phytohaemagglutinin[[14-19](#_ENREF_14)]. However, the costimulatory role of *DPP4*/CD26 is mediated by extra-enzymatic activities[[20-22](#_ENREF_20)]. Hence, some of the immunological effects observed in early *DPP4* inhibitor studies are now thought to be due to off-target non-selective inhibition of *DPP8* and *DPP9*[[2](#_ENREF_2),[23](#_ENREF_23),[24](#_ENREF_24)]. In support of this viewpoint, there is some evidence that *DPP8* and *DPP9* are functionally significant in the immune system. Their mRNA levels are elevated in activated human leukocytes[[25](#_ENREF_25),[26](#_ENREF_26)]. An inhibitor of *DPP8* and *DPP9* attenuates proliferation in *in vitro* models of human T-cell activation[[23](#_ENREF_23)]. An inhibitor selective for *DPP8* and *DPP9* versus related proteases can suppress DNA synthesis in mitogen-stimulated splenocytes from both wildtype *DPP4*+/+ and *DPP4*-/- gene knock out (GKO) mice[[27](#_ENREF_27)]. Moreover, *DPP8* and *DPP9* have been implicated in hematopoiesis and in inflammatory diseases including arthritis[[2](#_ENREF_2),[28](#_ENREF_28),[29](#_ENREF_29)]. Most importantly, *DPP8* and *DPP9* are involved in processing and degradation of peptides involved in antigen presentation by Major histocompatibility complex class I[[30](#_ENREF_30)].

Inflammatory and immune responses are important in liver injury. Improved understanding of immune response, inflammation and fibrogenic progression is needed to advance the understanding of liver disorders. *DPP8* and *DPP9* are expressed in hepatocytes and lymphocytes of human cirrhotic liver[[13](#_ENREF_13)]. Hepatocytes in the periseptal area of regenerative nodules and lymphocytes in the portal tracts are strongly positive for *DPP8* and *DPP9* *in situ* hybridization (ISH)[[13](#_ENREF_13)]. Bile ducts and ductular reactions are ISH positive for *DPP9* but not for *DPP8*[[13](#_ENREF_13)]. However, the role of *DPP8* and *DPP9* in liver is unknown. Other members of this protease family, *DPP4* and *FAP*, are altered in liver diseases and are potential disease markers and therapeutic targets[[31-36](#_ENREF_31)]. Despite the pleiotropic roles of *DPP4* and *FAP* in various biological processes, *DPP4* and *FAP* GKO mice exhibit no spontaneous defects, suggesting that *DPP4* and *FAP* are not essential for normal functions, and hence, targeting them is likely to lack adverse side effects[[37](#_ENREF_37),[38](#_ENREF_38)].

*DPP8* and *DPP9* have interesting properties in cell biological processes that may contribute to disease pathogenesis, such as apoptosis and cell migration[[39](#_ENREF_39),[40](#_ENREF_40)]. Their biological functions, especially in the immune system, are important considerations for the selectivity of *DPP4* inhibitors over *DPP8* and *DPP9* in clinical development of *DPP* antagonists. Here we studied the expression of *DPP8* and *DPP9* in lymphocyte activation, proliferation and apoptosis and in liver injury to elucidate their potential biological roles in the immune system and in liver diseases.

**Materials and Methods**

***Materials***

Antibodies are detailed in Table 1. Other materials were from Sigma-Aldrich (St Louis, MO, United States) unless stated.

***Animal studies***

Mice were maintained in the Centenary Institute animal facility under specific pathogen-free conditions. The Animal Ethics Committee of the University of Sydney approved experimental procedures and housing arrangements. *FAP* GKO[[38](#_ENREF_38)] and *DPP4* GKO mice[[37](#_ENREF_37)] (C57BL/6J background) were bred at the Animal Resource Centre (Perth, Australia). Female *Mdr2* GKO mice (FVB/N background) with targeted disruption of multidrug resistance gene (*Mdr2*) (Abcb4), were obtained from Jackson Laboratory (Jackson Laboratory, Bar Harbor, ME)[35]. Liver samples from the *Mdr2* GKO and WT mice were obtained at 4, 8 and 12 wk after birth, the time points that span the most active fibrosis progression[35]. RNA were obtained as previously described[[41](#_ENREF_41)]. Lymphocytes from WT, *DPP4* GKO and *FAP* GKO mouse spleen, liver and lymph nodes were isolated as previously described[[42](#_ENREF_42)].

For the liver fibrosis mouse model, 8 wk old female WT, *DPP4* GKO and *FAP* GKO mice were injected intraperitoneally with CCl4 twice weekly for 3 wk. Each dose comprised 5.36 μL of 12% CCl4 (in paraffin oil) per gram (g) of initial weight of each mouse. Significantly elevated alanine aminotransferase (ALT) (68 ± 11.1 U/L compared to untreated controls 32 ± 1.2 U/L) indicated liver injury. ALT was performed by an auto-analyzer at the Clinical Biochemistry Department of the Royal Prince Alfred Hospital. Organs were collected three days after the final CCl4 treatment.

***Human liver samples***

Human liver tissues were obtained from liver transplant recipients in accordance with National Health and Medical Research Council guidelines under Royal Prince Alfred Hospital Human Ethics Committee approvals. Non-diseased liver donors had an age range of 56 to 58 and mixed genders. Cirrhotic livers were from primary biliary cirrhosis (PBC) patients of average age 51.7 ± 13.3 years (range 27-67 years; 10 females, 2 males) and end stage alcoholic liver disease patients of average age 49.3 ± 8 years (range 34-60 years, 9 males) as described previously[[40](#_ENREF_40)].

***In vitro stimulation assays***

Human B lymphocyte Burkitt’s lymphoma cell line (Raji) (ATCC, CCL-86) and human T cell leukemia cell line (Jurkat) (ATCC, TIB-153) were cultured in RPMI Medium 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% Fetal Calf Serum (FCS) and Penicillin-Streptomycin (100units of penicillin and 100 μg/mL of streptomycin) (1×P/S) and Human liver hepatocellular carcinoma cell line Huh7 were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen) supplemented with 10% FCS and 1×P/S.

Lymphocytes at 1 × 106 cells/mL RPMI were treated with either 5 μg/mL Pokeweed mitogen (PWM), 20 μg/mL Lipopolysaccharide (LPS), 50 μg/mL Mitomycin C or 10 mmol/L dithiothreitol (DTT). Human liver hepatocellular carcinoma cell line, Huh7 cells were serum starved for 20 h before stimulation with 0, 1, 10, 100 ng/mL epidermal growth factor (EGF; R and D Systems, Minneapolis, United States) for 4 h.

***Apoptosis assay***

To determine if *DPP9* overexpression induces apoptosis, Raji cells were transiently transfected with wt*DPP9*-V5-His, mut*DPP9*-V5-His or vector control (pcDNA3.1/V5- HisA; Invitrogen, Carlsbad, CA) as described previously[[39](#_ENREF_39)], then cultured. The lymphocytes were transfected by electroporation using Amaxa® Cell Line Nucleofector® Kit V (Lonza, Basel, Switzerland) on a Lonza-amaxa Nucleofector device (Lonza). Forty hours post transfection, cells were washed with annexin binding buffer (10 mmol/L HEPES, 140 mmol/L NaCl, 2.5 mmol/L CaCl2, pH 7.4). Staining involved incubating cells with Annexin V antibody (Table 1) for 30 min at room temperature in the dark followed by 4',6-diamidino-2-phenylindole (DAPI, Sigma Aldrich) at 100 ng/mL. Cells were enumerated using flow cytometry. Analysis was performed using FlowJo software (Tree Star Inc., Ashland, United States).

***Fluorescence activated cell sorting***

To isolate mouse lymphocyte subsets, 3 × 107 splenocytes were resuspended in primary antibody diluted in PBS containing 1% FCS and incubated in the dark, on ice for 30 min. The primary antibodies used are listed in Table 1. Following antibody staining, cells were washed with PBS containing 1% FCS. Cells underwent a final resuspension of 2 × 107cells/mL of PBS with 5% FCS and 2 mmol/L EDTA to minimize clumping of cells. 25 μL/mL of DAPI was added prior to cell sorting. Cell sorting was performed using the Fluorescence Activated Cell Sorting VantageTM SE (BD Bioscience, NJ, United States). Cells were gated to exclude doublets and DAPI+ (dead) cells. Three-way sort was performed to collect CD4+ cells, CD8+ cells and B220+ cells into separate collection tubes.

***Real time quantitative*** ***polymerase chain reaction***

RNA from cells was extracted using the RNAqueous-MicroTM kit (Ambion, TX, United States) following manufacturer’s instructions. Total RNA (1 μg) was then reverse-transcribed to cDNA using 10 pmol of oligo(dT)12–18 primer (Invitrogen, Carlsbad, CA), 10 mmol/L dNTP and SuperScript III reverse transcriptase (Invitrogen). Real time quantitative Polymerase chain reaction (PCR) by Taqman® gene expression assays was performed using the Stratagene®Mx3000P™ System (La Jolla, CA, United States) according to manufacturer’s recommendations. Taqman primers used for the assays were mouse *DPP4* (Mm00494548\_mL), *DPP8* (Mm00547049\_mL) and *DPP9* (Mm00841122\_mL). The samples were run in duplicates. The gene expression level was analyzed using a standard curve of serially diluted known numbers of molecules of the same gene and then normalized relative to 18S (Hs99999901\_s1). Quantitative PCR on human samples were performed using sequence detector (Prism, model 7700; Life Technologies, NY, United States) and were analyzed using sequence detector software (Prism, version.1.6.3; Applied Biosystems, Inc.). Primers used for human *DPP8* were forward: 5’ CCAGATGGACCTCATTCAGACAG-3’ and reverse: 5’GGTTGTTGCGTAAATCCTTGTGG-3’ and for human *DPP9* were forward: 5’AGAAGCACCCCACCGTCCTCTTTG-3’ and reverse: 5’AGGACCAGCCATGGATGGCAACTC-3’. The number of molecules was normalized with human Aldolase B (forward: 5’-CCTCGCTATCCAGGAAAAC-3’ and reverse: 5’TTGTAGACAGCAGCCAGGAC-3’).

***Immunoblotting assay***

Cells were washed with ice-cold PBS three times and then lysed with ice-cold lysis buffer (50 mmol/L Tris-HCl, 1mmol/L EDTA, 1mmol/L MgCl2, 300 μL of 150 mmol/L NaCl, 1% Triton-114, 10% Glycerol and 1x Roche complete protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany) and stored at -80°C. Protein concentration was determined using the Micro BCA Protein Assay Kit (Thermo Scientific, CA, United States) following the manufacturer’s protocol. 50 μg total of each cell lysate in LDS sample buffer (catalogue No. NP0007, Invitrogen) with reducing agent (catalogue No. NP0004, Invitrogen) in conditions that retain *DPP8* and *DPP9* dimerization[[8](#_ENREF_8), [9](#_ENREF_9), [40](#_ENREF_40)] was resolved on 3-8% Tris-Acetate SDS-PAGE (Invitrogen) followed by immunoblotting. Antibodies for immunoblotting are listed in Table 1. Relative band intensities were quantified using Image J and normalized against control proteins as indicated[[40](#_ENREF_40)].

***Statistical analysis***

Results are expressed as individual replicates. Horizontal lines represent mean and error bars represent standard error. Differences among groups were analyzed using Mann-Whitney *t*-test by GraphPad Prism 5 software. *P* values < 0.05 were considered significant.

**Results**

To investigate which lymphocyte subsets express *DPP8* and *DPP9*, their transcript levels were quantified in the major lymphocyte subpopulations, CD4+ (helper) and CD8+ (cytotoxic) T cells and B220+ (B cells) from normal C57BL/6 mouse splenocytes. All three lymphocyte subsets expressed *DPP8* and *DPP9* mRNA (Figure 1). *DPP8* and *DPP9* transcripts were expressed to significantly greater levels than *DPP4* transcripts in CD4+ T cell subpopulation (*P =* 0.02) and *DPP9* mRNA was significantly more abundant than *DPP4* mRNA in B cells (*P =* 0.03).

To examine whether, like *DPP4*[7], *DPP8* and *DPP9* are upregulated upon lymphocyte activation, mouse splenocytes were stimulated *in vitro* with PWM[[43-45](#_ENREF_43)] and LPS[[46](#_ENREF_46), [47](#_ENREF_47)]. *DPP8* and *DPP9* mRNA was markedly upregulated in PWM stimulated mouse splenocytes in a time dependent manner (Figure 2A). To examine whether the increased mRNA levels corresponded to protein expression, *DPP8* and *DPP9* proteins were measured in Jurkat (T cells) stimulated in-vitro with PWM. Both *DPP8* and *DPP9* were upregulated in a time dependent manner (Figure 2B, C).

Similarly, mRNA levels of DPP8 and DPP9 were upregulated in LPS stimulated mouse splenocytes (Figure 3A). Also, LPS stimulated Raji (B cells) had upregulated DPP8 and DPP9 protein expression in a time dependent manner (Figure 3B, C).

Immunoblots of *DPP8* exhibited a slow mobility band at 150-180 kDa, which probably represents dimer or processed dimer, in addition to the faster mobility bands at 95 to 100 kDa that are likely to be monomer and truncated or trimmed monomer (Figure 2B, 3B). *DPP9* showed a slow mobility band of monomer at 110 kDa and faster mobility bands, which are possibly truncated or trimmed monomers at 75 to 95 kDa (Figure 2C, 3C)[[8](#_ENREF_8),[9](#_ENREF_9),[40](#_ENREF_40),[48](#_ENREF_48)]. The intensity of all three *DPP8* bands increased in a time dependent manner with PWM stimulation in Jurkat cells (Figure 2B). However, in LPS stimulated Raji cells the intensity of only the 150 kDa band increased in a time dependent manner (Figure 3B). The intensity of all the *DPP9* bands increased with time in both PWM stimulated Jurkat cells and LPS stimulated Raji cells (Figure 2C, 3C). In PWM stimulated Jurkat cells, *DPP8* and *DPP9* expression both peaked at 48 h (Figure 2B, C). In Raji cells, increased expression of *DPP8* was observed at 72 h post LPS stimulation (the longest time point of the study) (Figure 3B), and *DPP9* expression peaked at 60 h (Figure 3C).

***DPP8 and DPP9 in lymphocyte apoptosis***

We have previously shown that *DPP9* overexpression induces intrinsic cell apoptosis in human hepatoma and embryonic kidney cell lines[[39](#_ENREF_39), [40](#_ENREF_40)]. Similar to epithelial cells, *DPP9* overexpression induced increased cell death in Raji cells (Figure 4A). This effect was less pronounced when Raji cells were transfected with mutant *DPP9* lacking dipeptidyl peptidase activity (Figure 4A), suggesting that the enzyme activity of *DPP9* influences lymphocyte apoptosis.

Interestingly, Raji cells treated with DTT, an antioxidant that impairs cell apoptosis, had less *DPP8* and *DPP9* expression compared to untreated cells (Figure 4B, C). Conversely, treatment of Raji cells with mitomycin C, a lectin that impairs cell proliferation, resulted in increased *DPP8* and *DPP9* expression in Raji cells (Figure 4B, C). Intensities of all *DPP8* and *DPP9* band sizes were less with DTT treatment and greater with Mitomycin C treatment compared to untreated cells (Figure 4B, C).

***DPP9 in*** ***EGF stimulated hepatocytes***

 EGF is a regulatory factor in cell survival, growth, proliferation and differentiation[[49](#_ENREF_49)]. Previously, we have shown that *DPP9* overexpression impairs EGF-stimulated cell proliferation in HepG2 and Huh7 human hepatoma cell lines[[40](#_ENREF_40)]. *DPP9* expression at 75 kDa was greater in Huh7 cells after EGF stimulation (Figure 5). This study expands the association of *DPP9* with EGF in this hepatoma cell line.

***Intrahepatic DPP8 and DPP9 upregulation in CCl4 induced liver injury***

To examine *DPP8* and *DPP9* expression in liver injury, CCl4 was used to induce liver fibrosis in WT, *DPP4* GKO and *FAP* GKO mice. *DPP4*, *DPP8* and *DPP9* mRNA were significantly more abundant in the livers from CCl4 treated mice of all three genotypes compared to the untreated controls (Figure 6A). *DPP8* and *DPP9* mRNA expression in the CCL4 treated livers were greater in the *FAP* GKO mice compared to WT (*DPP8* *P =* 0.02; *DPP9* *P =* 0.02), suggesting that *DPP8* and *DPP9* might have compensatory roles in the absence of *FAP* (Figure 6A). The increase in *DPP9* mRNA in the fibrotic livers was consistent with protein expression in WT mice (*P =* 0.05) (Figure 6B). An appropriate antibody to mouse *DPP8* is not available.

Since *DPP8* and *DPP9* are expressed by human hepatic lymphocytes[[13](#_ENREF_13)] and because there is an increase of infiltrating lymphocytes in liver fibrosis, we examined whether the mouse hepatic lymphocytes were likely to contribute to the observed upregulation of *DPP* expression. However, *DPP* mRNA in the mouse hepatic lymphocytes was similar in the fibrotic and normal livers (Figure 6C).

***Intrahepatic DPP8 and DPP9 downregulation in biliary liver disease***

The *Mdr2* GKO mouse strain is deficient in the canalicular phospholipid flippase and is a model of periportal biliary fibrosis resembling primary sclerosing cholangitis[[41](#_ENREF_41)]. These mice develop spontaneous hepatomegaly as early as 2 wk after birth and significant biliary fibrosis with a fivefold increased liver collagen content by 12 wk of age, when no further fibrosis progression occurs[[41](#_ENREF_41)]. Measuring *DPP*s in these mice at 4, 8 and 12 wk of age showed that *DPP* mRNA expression was surprisingly very low at wk 4, significantly lower than in WT (*DPP8* *P =* 0.03; *DPP9* *P =* 0.03; *DPP4* *P =* 0.03) (Figure 7A). At 8 and 12 wk of age, *DPP* expression levels were similar to WT.

In human end-stage PBC livers, *DPP9* mRNA expression was significantly less than in the non-diseased livers (*P =* 0.03) (Figure 7B). This finding is consistent with the results in the *Mdr2* GKO mice and with the human *DPP9* Western blot data[[40](#_ENREF_40)]. *DPP8* mRNA expression levels in the non-diseased and PBC livers were not statistically different (*P =* 0.057).

**DISCUSSION**

This study significantly promotes our understanding of the novel proteases *DPP8* and *DPP9* in lymphocytes, hepatocytes and liver injury. We showed that *DPP8* and *DPP9* are widely expressed in lymphocyte subpopulations and upregulated in mitogen activated lymphocytes in a time dependent manner. Besides lymphocyte activation, we demonstrated their potential involvement in lymphocyte apoptosis. In liver, we showed that *DPP8* and *DPP9* expression levels were altered in liver injury and confirmed their role in the regulation of EGF in hepatocytes, a mitogen that is considered crucial for hepatocyte proliferation and liver regeneration. The interestingly variable expression patterns of *DPP8* and *DPP9* in different conditions in lymphocytes and in liver injury suggest that these proteases may have important regulatory roles in the immune system and in liver disease pathogenesis.

*DPP8*/9 activity and expression in lymphocytes have been reported previously[[8](#_ENREF_8),[30](#_ENREF_30),[50](#_ENREF_50)], but which lymphocyte subpopulations express *DPP8* and *DPP9* remained unknown. Here we show that all the lymphocyte subpopulations tested, CD4+ T cells, CD8+ T cells and B220+ B cells express *DPP8* and *DPP9*. The wide expression of *DPP8* and *DPP9* in lymphocyte subpopulations suggests that these proteases have essential roles in the immune system. As it is now known that immune roles of *DPP4* are mainly extraenzymatic (such as protein - protein interaction), greater abundance of *DPP8* and *DPP9* compared to *DPP4*/CD26 in the lymphocytes further supports the hypothesis that the immune effects with non-selective *DPP4* inhibitors in earlier studies were more likely due to *DPP8* and *DPP9* inhibition[[2](#_ENREF_2)].

We demonstrated a quantitative time-dependent upregulation of *DPP8* and *DPP9* in mitogen-stimulated mouse splenocytes and human Jurkat CD4+ T cells, as well as in polyclonally activated Raji B cells. Therefore, *DPP8* and *DPP9* might have roles in both T and B cell activation. *DPP8* and *DPP9* were upregulated in lymphocytes following acute mitogen stimulation, but with prolonged stimulation, they were downregulated. Hence, the role of *DPP8* and *DPP9* perhaps differ in recently activated lymphocytes compared to persistently activated lymphocytes.

*DPP9* enzyme activity induces intrinsic cell apoptosis in epithelial cells through the PI3K/Akt signaling pathway[[39](#_ENREF_39),[40](#_ENREF_40)]. Our data on Raji cells suggest that *DPP9* could similarly have a role in intrinsic lymphocyte apoptosis. Moreover the increase in *DPP8* and *DPP9* expression in mitomycin C treated cells is perhaps a hallmark of increased apoptosis in the absence of cell proliferation[[51](#_ENREF_51),[52](#_ENREF_52)]. *DPP9* substrates and ligands involved in these processes have not been identified.

The modulation of *DPP8* and *DPP9* expression with varying lymphocyte activation, proliferation and apoptosis, implies that *DPP8* and *DPP9* have important regulatory roles in lymphocytes that deserve further investigation. Their role in lymphocyte activation is likely to differ from that of *DPP4*. While the role of cell surface *DPP4* in lymphocyte proliferation appears to be mainly extra-enzymatic[[22](#_ENREF_22)], enzyme inhibition of intracellular *DPP8* and *DPP9* affects lymphocyte proliferation[[23](#_ENREF_23)]. The observation of less annexin V staining in Raji cells overexpressing *DPP9* enzyme mutant compared to wild type *DPP9* suggests that enzyme activity of *DPP9* is important for its role in apoptosis. *DPP9* modulates Akt phosphorylation in hepatoma cell lines[[40](#_ENREF_40)], so *DPP8* and *DPP9* might similarly modulate the activity of signaling molecules that are crucial in lymphocyte activation pathways. *DPP8* can cleave several chemokines, SDF-1α, SDF-1β, IP10 and ITAC, *in vitro*[[12](#_ENREF_12)], however since *DPP8* is an intracellular protease, the biological relevance of this cleavage is unknown.

The association of *DPP4* and *FAP* with liver fibrosis is well documented[[24](#_ENREF_24),[53](#_ENREF_53)]. Here we have demonstrated possible involvement of *DPP8* and *DPP9* in liver fibrosis, too. Treatment of mice with CCl4 for 3 wk, which represents early fibrosis with mild hepatic injury, increased intrahepatic *DPP8* and *DPP9* expression. This association with early stage disease may suggest pro-fibrogenic roles of *DPP8* and *DPP9*. Though *DPP*s have been implicated in inflammation and inflammatory diseases[[28](#_ENREF_28),[29](#_ENREF_29),[54](#_ENREF_54)], no change in *DPP* expression was observed in hepatic lymphocytes in this early stage fibrosis, suggesting that hepatocytes, which constitute more than 80% of the liver cell population, are probably the major source of upregulated *DPP8* and *DPP9* in this liver fibrosis model.

Unlike the CCl4 induced liver fibrosis model, *DPP8* and *DPP9* were downregulated in end stage human PBC and in the *Mdr2* GKO mice. This suggests that *DPP8* and *DPP9* expression varies with the pathophysiology of liver diseases. The mouse CCl4 model represents zone 3 fibrosis whereas *Mdr2* GKO represents a zone 1 fibrosis model[41,[55](#_ENREF_55)]. *DPP8* and *DPP9* show a zonal distribution pattern, with stronger staining in zone 3, the periseptal hepatocytes and periportal lymphocytes[[13](#_ENREF_13)]. Hence, the zonal injury pattern may be important for *DPP8* and *DPP9* expression. Another possibility could be that activated cholangiocytes downregulate *DPP8* and *DPP9* expression. In the *Mdr2* GKO mice, *DPP8* and *DPP9* expression was least at wk 4, when the cholangiocytes are most active[[41](#_ENREF_41)]. Hence, this could be the reason why *DPP8* and *DPP9* expression was downregulated in human PBC and *Mdr2* GKO mice.

Alternatively, the differential expression of *DPP* in the different liver diseases could be due to acute versus chronic stimuli. CCl4 induces acute liver injury with hepatocyte damage followed by a repair phase that involves increased collagen deposition[[55](#_ENREF_55)]. Administration of CCl4 twice per wk for 3 wk leads to repeated cycles of injury and repair that results in fibrosis. We collected liver samples from the CCl4 treated mice at day 3 after the last CCl4 injection. At day 3, hepatocyte apoptosis is waning whereas fibrosis is developing[[55](#_ENREF_55)]. In contrast, the *Mdr2* GKO mice and human end stage PBC represent chronic liver injury, whereby there is persistent (mild) hepatocyte damage, a fibrogenic cholangiocyte/progenitor cell response and downregulation of collagenolytic activity resulting in continuing progression of biliary fibrosis until week 12 of age[[41](#_ENREF_41)]. Thus, our data are consistent with the paradigm that *DPP8* and *DPP9* are upregulated in acute disease states then downregulated with progression to chronic disease states.

This distinctive *DPP* expression pattern in different liver diseases suggests that *DPP8* and *DPP9* have important regulatory roles in the pathogenesis of liver diseases, perhaps in modulating liver regeneration and apoptosis, which are important processes in liver disease progression. *DPP9* impairs EGF-stimulated hepatoma proliferation[[40](#_ENREF_40)]. Our observation that *DPP9* is upregulated in the presence of EGF is perhaps part of a regulatory mechanism of *DPP9* in hepatocyte proliferation. *DPP9* can induce intrinsic apoptosis in hepatoma cell lines via the Akt signaling pathway[[40](#_ENREF_40)]. Furthermore, *DPP8* and *DPP9* influence cell-extracellular matrix (ECM) interactions *in vitro*[[39](#_ENREF_39)] and in liver fibrogenesis, cell-ECM interaction is responsible for disrupting wound healing and progressive scarring in liver disease[[56](#_ENREF_56)].

The upregulated expression of *DPP8* and *DPP9* in acute conditions and less expression in chronic or persistent conditions in the immune system and in liver injury suggests that *DPP8* and *DPP9* are crucial for early cellular responses to stimuli. The mechanisms of *DPP8* and *DPP9* are yet to be elucidated. One obstacle in *DPP8* and *DPP9* studies is the poor availability of appropriate tools, such as monoclonal antibodies and selective inhibitors[[57](#_ENREF_57)].

In conclusion, our study suggests that *DPP8* and *DPP9* have fundamental roles in the immune system, in lymphocyte activation and in apoptosis and they could be involved in liver fibrogenesis. A better understanding of the biological functions of *DPP8* and *DPP9* could help reveal their therapeutic potential for liver diseases, cancer, inflammatory and autoimmune diseases.

**ACKNOWLEDGMENTS**

We thank the Royal Prince Alfred Hospital National Liver Transplant Unit for providing human liver samples, Michelle Vo for advice, Adrian Smith and Robert Salomon of the Centenary Institute Flow Cytometry Facility for their expert cell sorting.

**COMMENTS**

***Background***

The four enzyme members of the dipeptidyl peptidase (*DPP*) 4 gene family, *DPP4*, fibroblast activation protein (FAP), *DPP8* and *DPP9* have attracted considerable research interest in recent years since *DPP4* inhibitors became a successful therapy for type 2 diabetes and FAP a potential cancer therapeutic target. *DPP8* and *DPP9* are the more recently discovered members of the *DPP4* gene family. They are ubiquitously expressed cytoplasmic enzymes with *DPP4* like enzyme activity. Many compounds intended to inhibit *DPP4* or FAP also inhibit *DPP8* and *DPP9*, but the compounds that became successful diabetes drugs are *DPP4*-selective.

***Research frontiers***

*DPP4* is also known as CD26 T cell differentiation marker and has roles in T cell activation and proliferation. *DPP8* and *DPP9* are in lymphoid tissues and may have functional significance in the immune system. *DPP8* and *DPP9* are expressed in hepatocytes and expression is elevated in damaged hepatocytes near the septum of human cirrhotic liver. However, potential roles of *DPP8* and *DPP9* in liver disease are unknown. Here the authors studied the expression of *DPP8* and *DPP9* in lymphocyte activation, proliferation and apoptosis and in liver injury models to elucidate their potential biological roles in the immune system and in liver diseases. Models included hepatotoxicity from CCl4, and the *Mdr2*-/- mouse that spontaneously develops biliary fibrosis.

***Innovations and breakthroughs***

This study significantly promotes our understanding of the novel proteases *DPP8* and *DPP9* in lymphocytes, hepatocytes and liver injury. The authors showed that *DPP8* and *DPP9* were widely expressed in lymphocyte subpopulations and were upregulated in activated lymphocytes in a time dependent manner. The authors also demonstrated potential involvement of *DPP8* and *DPP9* in lymphocyte apoptosis. In liver, we showed that *DPP8* and *DPP9* expression levels were altered in liver injury and confirmed their role in the regulation of epidermal growth factor in hepatocytes, a mitogen that is considered crucial for hepatocyte proliferation and liver regeneration.

***Applications***

This study suggests that *DPP8* and *DPP9* have fundamental roles in the immune system, in lymphocyte activation and in apoptosis and they could be involved in chronic liver injury pathogenesis.

***Terminology***

To describe concisely and accurately any terms that may not be familiar to the majority of the readers, but are essential for understanding the article; *DPP4* enzyme activity is a specialized proteolytic enzyme activity that cuts two amino acids from the N-terminus of each target peptide, usually cutting after a proline residue; Lymphocyte activation is a cellular process that leads to a radical shift in cell behavior to a more active and proliferative one. The activation of lymphocytes serves two purposes, augmenting the number of cells to respond to a particular antigen (clonal expression), and specializing to produce cytokines, and produce antibodies against a pathogen; Cell apoptosis is the process of cell death mediated by an intracellular program. Apoptosis is important for normal cell turnover and organ remodeling.

***Peer review***

The manuscript deals with regulation of *DPP8* and *DPP9* expression in activated lymphocytes and injured liver. Here the authors focus on the expression levels of *DPP8* and *DPP9* in lymphocyte subpopulations in a time dependent manner. The authors have confirmed the altered expression level of *DPP8* and *DPP9* in liver injury and also confirmed their role in the regulation of EGF in hepatocytes. The work has been carefully conducted and the experiments are clearly described in the vast majority of the cases.

**REFERENCES**

1 **Rosenblum JS**, Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. *Curr Opin Chem Biol* 2003; **7**: 496-504 [PMID: 12941425 DOI: 10.1016/S1367-5931(03)00084-X]

2 **Yu DM**, Yao TW, Chowdhury S, Nadvi NA, Osborne B, Church WB, McCaughan GW, Gorrell MD. The dipeptidyl peptidase IV family in cancer and cell biology. *FEBS J* 2010; **277**: 1126-1144 [PMID: 20074209 DOI: 10.1369/jhc.2009.953760]

3 **Keane FM**, Chowdhury S, Yao T-W, Nadvi NA, Gall MG, Chen Y, Osborne B, Vieira de Ribeiro AJ, Church WB, McCaughan GW, Gorrell MD, Yu DMT Targeting Dipeptidyl Peptidase-4 (*DPP*-4) and Fibroblast Activation Protein (*FAP*) for diabetes and cancer therapy. In Dunn B (ed.), Proteinases as Drug Targets. Royal Society of Chemistry, Cambridge, UK, Vol. 2011: p. 119-145

4 **Gossrau R**. [Peptidases II. Localization of dipeptidylpeptidase IV (*DPP* IV). Histochemical and biochemical study]. *Histochemistry* 1979; **60**: 231-248 [PMID: 457448 DOI: 10.1007/BF00495756]

5 **Hartel S**, Gossrau R, Hanski C, Reutter W. Dipeptidyl peptidase (*DPP*) IV in rat organs. Comparison of immunohistochemistry and activity histochemistry. *Histochemistry* 1988; **89**: 151-161 [PMID: 2456278 DOI: 10.1007/BF00489918]

6 **McCaughan GW**, Wickson JE, Creswick PF, Gorrell MD. Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis by tissue distribution, purification and N-terminal amino acid sequence. *Hepatology* 1990; **11**: 534-544 [PMID: 1970322 DOI: 10.1002/hep.1840110403]

7 **Gorrell MD**, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. *Scand J Immunol* 2001; **54**: 249-264 [PMID: 11555388 DOI: 10.1046/j.1365-3083.2001.00984.x]

8 **Abbott CA**, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (*DPP*) IV homolog, *DPP8*. *Eur J Biochem* 2000; **267**: 6140-6150 [PMID: 11012666 DOI: 10.1046/j.1432-1327.2000.01617.x]

9 **Ajami K**, Abbott CA, McCaughan GW, Gorrell MD. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. *Biochim Biophys Acta* 2004; **1679**: 18-28 [PMID: 15245913 DOI: 10.1016/j.bbaexp.2004.03.010]

10 **Olsen C**, Wagtmann N. Identification and characterization of human *DPP9*, a novel homologue of dipeptidyl peptidase IV. *Gene* 2002; **299**: 185-193 [PMID: 12459266 DOI: 10.1016/S0378-1119(02)01059-4]

11 **Qi SY**, Riviere PJ, Trojnar J, Junien JL, Akinsanya KO. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. *Biochem J* 2003; **373**: 179-189 [PMID: 12662155]

12 **Ajami K**, Pitman MR, Wilson CH, Park J, Menz RI, Starr AE, Cox JH, Abbott CA, Overall CM, Gorrell MD. Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. *FEBS Lett* 2008; **582**: 819-825 [PMID: 18275857 DOI: 10.1016/j.febslet.2008.02.005]

13 **Yu DM**, Ajami K, Gall MG, Park J, Lee CS, Evans KA, McLaughlin EA, Pitman MR, Abbott CA, McCaughan GW, Gorrell MD. The in vivo expression of dipeptidyl peptidases 8 and 9. *J Histochem Cytochem* 2009; **57**: 1025-1040 [PMID: 19581630]

14 **Fleischer B**. A novel pathway of human T cell activation via a 103 kD T cell activation antigen. *J Immunol* 1987; **138**: 1346-1350 [PMID: 3100637]

15 **Gorrell MD**, Miller HR, Brandon MR. Lymphocyte phenotypes in the abomasal mucosa of sheep infected with Haemonchus contortus. *Parasite Immunol* 1988; **10**: 661-674 [PMID: 3217127]

16 **Heike M**, Möbius U, Knuth A, Meuer S, Meyer zum Büschenfelde KH. Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. *Clin Exp Immunol* 1988; **74**: 431-434 [PMID: 2466591]

17 **Marguet D**, Bernard AM, Vivier I, Darmoul D, Naquet P, Pierres M. cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases. *J Biol Chem* 1992; **267**: 2200-2208 [PMID: 1370813]

18 **Schön E**, Ansorge S. Dipeptidyl peptidase IV in the immune system. Cytofluorometric evidence for induction of the enzyme on activated T lymphocytes. *Biol Chem Hoppe Seyler* 1990; **371**: 699-705 [PMID: 1698386 DOI: 10.1515/bchm3.1990.371.2.699]

19 **Kahne T**, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). *Int J Mol Med* 1999; **4**: 3-15 [PMID: 10373631]

20 **Hühn J**, Ehrlich S, Fleischer B, von Bonin A. Molecular analysis of CD26-mediated signal transduction in T cells. *Immunol Lett* 2000; **72**: 127-132 [PMID: 10841948 DOI: 10.1016/S0165-2478(00)00170-X]

21 **Kirby M**, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. *Clin Sci (Lond)* 2010; **118**: 31-41 [PMID: 19780719 DOI: 10.1042/CS20090047]

22 **Yu DM**, Slaitini L, Gysbers V, Riekhoff AG, Kähne T, Knott HM, De Meester I, Abbott CA, McCaughan GW, Gorrell MD. Soluble CD26 / dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. *Scand J Immunol* 2011; **73**: 102-111 [PMID: 21198750 DOI: 10.1111/j.1365-3083.2010.02488.x]

23 **Lankas GR**, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, Chan CC, Edmondson S, Feeney WP, He H, Ippolito DE, Kim D, Lyons KA, Ok HO, Patel RA, Petrov AN, Pryor KA, Qian X, Reigle L, Woods A, Wu JK, Zaller D, Zhang X, Zhu L, Weber AE, Thornberry NA. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. *Diabetes* 2005; **54**: 2988-2994 [PMID: 16186403 DOI: 10.2337/diabetes.54.10.2988]

24 **Gorrell MD**. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. *Clin Sci (Lond)* 2005; **108**: 277-292 [PMID: 15584901 DOI: 10.1042/CS20040302]

25 **Abbott CA**, Yu D, McCaughan GW, Gorrell MD. Post-proline-cleaving peptidases having DP IV like enzyme activity. Post-proline peptidases. *Adv Exp Med Biol* 2000; **477**: 103-109 [PMID: 10849735]

26 **Bank U**, Heimburg A, Wohlfarth A, Koch G, Nordhoff K, Julius H, Helmuth M, Breyer D, Reinhold D, Täger M, Ansorge S. Outside or inside: role of the subcellular localization of DP4-like enzymes for substrate conversion and inhibitor effects. *Biol Chem* 2011; **392**: 169-187 [PMID: 21194378 DOI: 10.1515/BC.2011.025]

27 **Reinhold D**, Goihl A, Wrenger S, Reinhold A, Kühlmann UC, Faust J, Neubert K, Thielitz A, Brocke S, Täger M, Ansorge S, Bank U. Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice. *Clin Chem Lab Med* 2009; **47**: 268-274 [PMID: 19676138 DOI: 10.1515/CCLM.2009.062]

28 **von Bonin A**, Hühn J, Fleischer B. Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway. *Immunol Rev* 1998; **161**: 43-53 [PMID: 9553763 DOI: 10.1111/j.1600-065X.1998.tb01570.x]

29 **Tanaka S**, Murakami T, Horikawa H, Sugiura M, Kawashima K, Sugita T. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. *Int J Immunopharmacol* 1997; **19**: 15-24 [PMID: 9226475 DOI: 10.1016/S0192-0561(97)00004-0]

30 **Geiss-Friedlander R**, Parmentier N, Möller U, Urlaub H, Van den Eynde BJ, Melchior F. The cytoplasmic peptidase *DPP9* is rate-limiting for degradation of proline-containing peptides. *J Biol Chem* 2009; **284**: 27211-27219 [PMID: 19667070 DOI: 10.1074/jbc.M109.041871]

31 **Matsumoto Y**, Bishop GA, McCaughan GW. Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver. *Hepatology* 1992; **15**: 1048-1053 [PMID: 1350563 DOI: 10.1002/hep.184015061]

32 **Stecca BA**, Nardo B, Chieco P, Mazziotti A, Bolondi L, Cavallari A. Aberrant dipeptidyl peptidase IV (*DPP* IV/CD26) expression in human hepatocellular carcinoma. *J Hepatol* 1997; **27**: 337-345 [PMID: 9288609 DOI: 10.1016/S0168-8278(97)80180-8]

33 **Levy MT**, McCaughan GW, Abbott CA, Park JE, Cunningham AM, Müller E, Rettig WJ, Gorrell MD. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. *Hepatology* 1999; **29**: 1768-1778 [PMID: 10347120 DOI: 10.1002/hep.510290631]

34 **Cox G**, Kable E, Jones A, Fraser I, Manconi F, Gorrell MD. 3-dimensional imaging of collagen using second harmonic generation. *J Struct Biol* 2003; **141**: 53-62 [PMID: 12576020 DOI: 10.1016/S1047-8477(02)00576-2]

35 **Wang XM**, Yu DM, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. *Hepatology* 2005; **42**: 935-945 [PMID: 16175601 DOI: 10.1002/hep.20853]

36 **Lo L**, McLennan SV, Williams PF, Bonner J, Chowdhury S, McCaughan GW, Gorrell MD, Yue DK, Twigg SM. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. *J Hepatol* 2011; **55**: 435-444 [PMID: 21184785 DOI: 10.1016/j.jhep.2010.10.039]

37 **Marguet D**, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. *Proc Natl Acad Sci U S A* 2000; **97**: 6874-6879 [PMID: 10823914 DOI: 10.1073/pnas.120069197]

38 **Niedermeyer J**, Kriz M, Hilberg F, Garin-Chesa P, Bamberger U, Lenter MC, Park J, Viertel B, Püschner H, Mauz M, Rettig WJ, Schnapp A. Targeted disruption of mouse fibroblast activation protein. *Mol Cell Biol* 2000; **20**: 1089-1094 [PMID: 10629066 DOI: 10.1128/MCB.20.3.1089-1094.2000]

39 **Yu DM**, Wang XM, McCaughan GW, Gorrell MD. Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. *FEBS J* 2006; **273**: 2447-2460 [PMID: 16704418 DOI: 10.1111/j.1742-4658.2006.05253.x]

40 **Yao TW**, Kim WS, Yu DM, Sharbeen G, McCaughan GW, Choi KY, Xia P, Gorrell MD. A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling. *Mol Cancer Res* 2011; **9**: 948-959 [PMID: 21622624 DOI: 10.1158/1541-7786.MCR-10-0272]

41 **Popov Y**, Patsenker E, Fickert P, Trauner M, Schuppan D. *Mdr2* (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. *J Hepatol* 2005; **43**: 1045-1054 [PMID: 16223543 DOI: 10.1016/j.jhep.2005.06.025]

42 **Holz LE**, Benseler V, Bowen DG, Bouillet P, Strasser A, O'Reilly L, d'Avigdor WM, Bishop AG, McCaughan GW, Bertolino P. Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. *Gastroenterology* 2008; **135**: 989-997 [PMID: 18619445 DOI: 10.1053/j.gastro.2008.05.078]

43 **Wallays G**, Ceuppens JL. Human T lymphocyte activation by pokeweed mitogen induces production of TNF-alpha and GM-CSF and helper signaling by IL-1 and IL-6 results in IL-2-dependent T cell growth. *Eur Cytokine Netw* ; **4**: 269-277 [PMID: 8268417]

44 **Barcellini W**, Sguotti C, Dall'Aglio P, Garelli S, Meroni PL. In vitro immunoglobulin synthesis: T-cell requirement in pokeweed and staphylococcus aureus B-cell activation. *J Clin Lab Immunol* 1985; **17**: 177-181 [PMID: 3877812]

45 **Serke S**, Serke M, Brudler O. Lymphocyte activation by phytohaemagglutinin and pokeweed mitogen. Identification of proliferating cells by monoclonal antibodies. *J Immunol Methods* 1987; **99**: 167-172 [PMID: 3108406 DOI: 10.1016/0022-1759(87)90122-0]

46 **Dye JR**, Palvanov A, Guo B, Rothstein TL. B cell receptor cross-talk: exposure to lipopolysaccharide induces an alternate pathway for B cell receptor-induced ERK phosphorylation and NF-kappa B activation. *J Immunol* 2007; **179**: 229-235 [PMID: 17579042]

47 **Wade WF**. B-cell responses to lipopolysaccharide epitopes: Who sees what first - does it matter? *Am J Reprod Immunol* ; **56**: 329-336 [PMID: 17076677 DOI: 10.1111/j.1600-0897.2006.00433.x]

48 **Dubois V**, Lambeir AM, Van der Veken P, Augustyns K, Creemers J, Chen X, Scharpé S, De Meester I. Purification and characterization of dipeptidyl peptidase IV-like enzymes from bovine testes. *Front Biosci* 2008; **13**: 3558-3568 [PMID: 18508455 DOI: 10.2741/2949]

49 **Yarden Y**, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol* 2001; **2**: 127-137 [PMID: 11252954 DOI: 10.1038/35052073]

50 **Maes MB**, Dubois V, Brandt I, Lambeir AM, Van der Veken P, Augustyns K, Cheng JD, Chen X, Scharpé S, De Meester I. Dipeptidyl peptidase 8/9-like activity in human leukocytes. *J Leukoc Biol* 2007; **81**: 1252-1257 [PMID: 17287297 DOI: 10.1189/jlb.0906546]

51 **Pirnia F**, Schneider E, Betticher DC, Borner MM. Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway. *Cell Death Differ* 2002; **9**: 905-914 [PMID: 12181741 DOI: 10.1038/sj.cdd.4401062]

52 **Kloner RA**. No reflow revisited. *J Am Coll Cardiol* 1989; **14**: 1814-1815 [PMID: 2584573 DOI: 10.1073/pnas.0807185105]

53 **Wang XM**, Yao TW, Nadvi NA, Osborne B, McCaughan GW, Gorrell MD. Fibroblast activation protein and chronic liver disease. *Front Biosci* 2008; **13**: 3168-3180 [PMID: 17981786 DOI: 10.2741/2918]

54 **De Meester I**, Korom S, Van Damme J, Scharpé S. CD26, let it cut or cut it down. *Immunol Today* 1999; **20**: 367-375 [PMID: 10431157 DOI: 10.1016/S0167-5699(99)01486-3]

55 **Novobrantseva TI**, Majeau GR, Amatucci A, Kogan S, Brenner I, Casola S, Shlomchik MJ, Koteliansky V, Hochman PS, Ibraghimov A. Attenuated liver fibrosis in the absence of B cells. *J Clin Invest* 2005; **115**: 3072-3082 [PMID: 16276416 DOI: 10.1172/JCI24798]

56 **Friedman SL**. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. *J Biol Chem* 2000; **275**: 2247-2250 [PMID: 10644669 DOI: 10.1074/jbc.275.4.2247]

57 **Van Goethem S**, Matheeussen V, Joossens J, Lambeir AM, Chen X, De Meester I, Haemers A, Augustyns K, Van der Veken P. Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (*DPP8*, *DPP9*): is *DPP8*-selectivity an attainable goal? *J Med Chem* 2011; **54**: 5737-5746 [PMID: 21711053 DOI: 10.1021/jm200383j]

**P-reviewer** Shembade ND **S-Editor** Jiang L **L-Editor E-Editor**

**Figure 1** **Dipeptidyl peptidase mRNA expression in C57BL/6 mouse splenic lymphocyte subpopulations.** Number of molecules relative to 18S RNA. *n* = 4-6 mice. DPP: Dipeptidyl peptidase; a*P* < 0.05 compared to DPP4.

**Figure 2** **Dipeptidyl peptidase 8 and Dipeptidyl peptidase 9 upregulation in Pokeweed mitogen stimulated lymphocytes.** A: Dipeptidyl peptidase (*DPP*) 8 and *DPP9* mRNA in mouse splenocytes (representative data from one of three mice); *DPP8* and *DPP9* proteins frSom Jurkat cells; B: immunoblot of *DPP8* and densitometry analysis of *DPP8* bands; C: immunoblot of *DPP9* and densitometry analysis of bands. Densitometry data shown are relative to glyceraldehyde 3-phosphate dehydrogenase.

**Figure 3 Dipeptidyl peptidase 8 and Dipeptidyl peptidase 9 upregulation in lipopolysaccharide stimulated lymphocytes.** A: Dipeptidyl peptidase (*DPP*) 8 and *DPP9* mRNA in mouse splenocytes (representative data from one of three mice); *DPP8* and *DPP9* protein from Raji cells (B): immunoblot of *DPP8* and densitometry analysis of *DPP8* bands (C) *DPP9* immunoblot and densitometry analysis of *DPP9* bands relative to glyceraldehyde 3-phosphate dehydrogenase.

**Figure 4** **Dipeptidyl peptidase 8 and Dipeptidyl peptidase 9 were associated with lymphocyte apoptosis.** A: Percentage of Annexin V+ Raji cells 40 h after transfection with vector, wt Dipeptidyl peptidase (*DPP*)9-V5-His or enzyme-negative mut*DPP9*-V5-His. Annexin V staining was enumerated by flow cytometry; B: Immunoblot of *DPP8* and its densitometry (C) Immunoblot of *DPP9* and its densitometry in Raji cells untreated and treated with DTT or Mitomycin C for 24 h. Densitometry are shown as relative to glyceraldehyde 3-phosphate dehydrogenase. DTT: Dithiothreitol.

**Figure 5** **Dipeptidyl peptidase 9 upregulation in EGF treated Huh7 cells**. Dipeptidyl peptidase (*DPP*)9 immunoblot of untreated and EGF-treated Huh7 cells at 4 h. Cells were serum starved overnight before EGF treatment. Densitometry of *DPP9* is shown relative to Actin.

**Figure 6** **Dipeptidyl peptidase mRNA upregulation in CCl4 induced liver injury.** A: Multiple of intrahepatic mRNA in CCl4 treated mice to mean of untreated control mice; a*P* < 0.05 in CCl4 treated FAP gko compared to WT; B: *DPP9* immunoblot of livers from CCl4 treated (lane 1-6) and untreated mice (lane 7-12) (*n* = 6 per group): Densitometry of intrahepatic *DPP9* relative to GAPDH. c*P* < 0.05 compared to untreated controls; C: mRNA quantitation from isolated hepatic lymphocytes relative to 18S.

**Figure 7 Dipeptidyl peptidase mRNA in mouse and human biliary liver diseases.** A: Multiple of Intrahepatic *DPP* mRNA in *Mdr2* KO female mice to mean of WT controls. a*P* <0.05 compared to WT controls; B: Human end-stage PBC and non-diseased control livers. Data from each individual is shown as the number of molecules relative to Aldolase B (*n* = 4 per group). c*P* < 0.05 compared to non-diseased control livers.

 **Table 1 Antibodies used in immunoblot and flow cytometry**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Name** | **Isotype** | **Conjugate** | **Dilution** | **Supplier** | **Catalogue No.** |
| Primary antibodies |
| CD4 | Rat immunoglobulin (IgG)2b | FITC | 1:50 | BD Pharmingen, NJ, United States | 557307 |
| B220 | Rat IgG | PE | 1:50 | Caltag Laboratories, CA, United States | RM2604-3 |
| CD8 | Rat IgG2a | APC | 1:50 | BD Pharmingen, NJ, United States | 553035 |
| Annexin V |  | APC | 1:50 | BD Pharmingen, NJ, UNITED STATES | 550474 |
| V5 | Mouse monoclonal IgG2a |  | 1:5000 | Invitrogen | R960-25 |
| DPP8- Catalytic domain | Rabbit polyclonal |  | 1:2000 | Abcam Inc | Ab42077 |
| DPP8- Catalytic domain | Rabbit polyclonal |  | 1:2000 | Abcam Inc | Ab42076 |
| DPP9- Catalytic domain | Rabbit polyclonal |  | 1:2000 | Abcam Inc | Ab42080 |
| GAPDH | Mouse monoclonal |  | 1:1000 | EnCor Biotechnology | MCA-1D4 |
| β-Actin | Rabbit polyclonal |  | 1:1000 | Sigma | A2103 |
| Secondary antibodies |
| Anti-Rabbit IgG | Goat | HRP | 1:3000 | DAKO (Carpinteria, CA) | PO448 |
| Anti-Mouse | Goat IgG | R-PE | 1:400 | Molecular Probes | P852 |

GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; FITC: Fluorescein; PE: Phycoerythrin; APC: Allophycocyanin; HRP: Horse Radish Peroxidase; RPE: R-phycoerythrin.